ProCE Banner Activity

Venetoclax + Azacitidine vs Azacitidine Monotherapy in Chemotherapy-Ineligible Patients With tAML or AML From Antecedent MDS or CMML

Slideset Download
Conference Coverage
Pooled analysis of clinical data suggests that venetoclax + azacitidine is both safe and efficacious in patients with secondary AML unfit for chemotherapy, including individuals with intermediate- or poor-risk cytogenetics.

Released: June 06, 2021

Expiration: June 05, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme